{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-013563","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.986241+00:00","generated_at":"2026-06-06T04:12:11.333741+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Larimar reports positive Phase 2 nomlabofusp data; frataxin dose response up to 5.57 pg/µg in skin","bullets":["50 mg cohort: median FXN increase in skin 5.57 pg/µg at day 14; all patients reached >33% healthy volunteer level.","25 mg cohort: median FXN increase in skin 2.81 pg/µg; one allergic AE resolved; 18 of 19 completed.","Cash $86.8M as of Dec 31, 2023; expected runway into Q1 2025.","OLE initiated Jan 2024 starting 25 mg daily; interim data expected Q4 2024.","FDA discussions ongoing for accelerated approval using FXN as surrogate; BLA submission targeted 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-013563","json":"https://secwatch.observer/filing/0000950170-24-013563.json","markdown":"https://secwatch.observer/filing/0000950170-24-013563.md","text":"https://secwatch.observer/filing/0000950170-24-013563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024013563/0000950170-24-013563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024013563/lrmr-20240212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:12:11.333741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}